Table 3.

a Risk factors stratified by primary endpoints defined as time to arrhythmic death (AD) or resusci- tated cardiac arrest (RCA) and all other deaths using first (I1) and second (I2) investigation.
	N	Alive n=87	Arrhythmic death /resuscitated car-diac ar- rest, n=40	Death other n=23	P- value
Autonomic tone
BRS_I1, ms/mmHG, Med	92	9·6 (6·0–13·8)	6.8 (4.8–9.9)	6·5 (1·3–11·9)	0.13
BRS_I2, ms/mmHG, Med	105	10·9 (6·5– 17·3)	5.7 (3.2–11.6)	6·4 (1·8–11·4)	0.002
LF/HF_I1, LF to HF ratio, Med	109	2·4 (1·3–4·0)	2.1 (0.9–3.7)	2·0 (0·7–3·8)	0.51
LF/HF_I2, LF to HF ratio, Med	112	2·8 (1·4–5·1)	2.3 (0.8–4.6)	1·9 (0·8–3·7)	0.28
HRV_I1, SDNN, ms, Med	103	114 (97–134)	105 (77–134)	116 (84–131)	0.51
HRV_I2, SDNN, ms, Med	92	115 (95–140)	110 (93–127)	85 (65–105)	0.051
Electrical substrate
PVS_I1	85				0.061
Negative		8 (24)	13 (11)	6 (43)
Non-negative		25 (76)	25 (89)	8 (57)
SAECG_I1	112				0.37
Negative		30 (51)	22 (61)	7 (41)
Non-negative		29 (49)	14 (39)	10 (59)
SAECG_I2	98				0.36
Negative		49 (68)	9 (50)	5 (62)
Non-negative		23 (32)	9 (50)	3 (38)
MTWA_I1	150				<0.001
Negative		68 (78)	7 (18)	15 (65)
Non-negative		19 (22)	33 (82)	8 (35)
MTWA_I2	132
Negative		68 (80)	2 (7)	9 (50)	<0.001
Non-negative		17 (20)	27 (93)	9 (50)
Clinical variables		68 (80)	2 (7)	9 (50)	<0.001
History of syncope_I1	150	15 (17)	11 (28)	14 (17)	0.38
Non-sustained VT_I1	111	11 (19)	12 (33)	5 (29)	0.27
LVEF_I1, %, Med	150	39 (30–65)	33 (29–37)	35 (28–40)	<0.001
LVEF_I2, %, Med	131	38 (29–65)	30 (25–37)	30 (23–35)	<0.001
QTC_I1, ms, Med	150	436 (424–453)	454 (443–464)	464 (428–474)	0.084
QTC_I2, ms, Med	131	435 (419–458)	472 (443–481)	460 (421–468)	0.13
Crea_I1, mg/dl, Med	150	1.2 (1.0–1.5)	1.2 (1.0–1.3)	1.5 (1.0–1.9)	0.41
Crea_I2, mg/dl, Med	131	1.2 (1.0–1.4)	1.2 (1.0–1.3)	1.5 (1.1–1.7)	0.37

b Risk factors stratified by secondary endpoints defined as time to cardiac death (CD) and non- cardiac death using first (I1) and second (I2) investigation.
	N	Alive, n=104	Cardiac death, n=34	Non-cardiac death, n=12	P- value
Autonomic tone
BRS_I1, ms/mmHG, Med	92	9.6 (6.0–14.5)	6.3 (2.6–8.3)	7.3 (4.2–13.0)	0.008
BRS_I2, ms/mmHG, Med	105	10.7 (6.1–17.2)	4.7 (0.3–6.7)	7.9 (2.2–13.7)	0.001
LF/HF_I1, LF to HF ratio, Med	109	2.5 (1.2–4.4)	1.9 (0.7–2.9)	1.1 (0.6–3.3)	0.06
LF/HF_I2, LF to HF ratio, Med	112	2.8 (1.3–5.3)	1.5 (0.4–2.3)	3.5 (0.9–3.7)	0.047
HRV_I1, SDNN, ms, Med	103	117 (100–140)	84 (67–116)	123 (108–134)	0.003
HRV_I2, SDNN, ms, Med	92	114 (96–140)	94 (82–116)	63 (60–74)	0.003
Electrical substrate
MTWA_I1	150				<0.001
Negative		74 (71)	9 (26)	7 (58)
Non-negative		30 (29)	25 (74)	5 (42)
MTWA_I2	132
Negative		69 (68)	4 (18)	6 (75)	<0.001
Non-negative		33 (32)	18 (82)	2 (25)
Clinical variables
LVEF_I1, %, Med	150	38 (30–58)	32 (27–37)	38 (33–42)	0.002
LVEF_I2, %, Med	131	37 (28–60)	28 (20–34)	35 (25–37)	<0.001

c: Cox proportional-hazards model using baseline clinical variables for arrhythmic death / resusci- tated death in ischemic heart disease patients alone.
Parameter	Haz- ard Ratio	95%C I low- er	95% CI upper	p- value
(LV)EF (10% increase)	0.97	0.92	1.02	0.212
MTWA (non- negative:negative)	0.15	0.06	0.41	0.008
BRS (1 unit increase)	0.95	0.89	1.01	0.127
SDNN (10 units increase)	0.99	0.98	1.00	0.184

Data are n (%), unless otherwise indicated; Med=median (Q1–Q3); I1, I2 Investigation 1 and 2, N is the number of non-missing values; test used: Kruskal-Wallis test